Results 231 to 240 of about 89,952 (300)

Early‐Onset Digestive System Cancers: Risk Factors and Clinicopathological and Molecular Features Across Organ Sites

open access: yesCancer Science, Volume 117, Issue 5, Page 1223-1234, May 2026.
Shared risk factors, clinical features, and tumor characteristics across multiple early‐onset cancer types are shown in this Graphical Abstract. Integrative approaches combining molecular pathology, oncology, and population sciences offer opportunities to clarify underlying mechanisms and help us develop preventive strategies for early‐onset cancers ...
Nobuhiro Nakazawa   +17 more
wiley   +1 more source

CD8+ T Cell Infiltration Elicits Molecular Subtype‐Biased Clinical Outcomes in Gastric Cancer Patients

open access: yesCancer Science, Volume 117, Issue 5, Page 1434-1445, May 2026.
CD8+ T cell infiltration demonstrates distinct clinical significance across molecular subtypes of gastric cancer. High infiltration correlates with improved survival in EBV‐positive and CIN subtypes, while low infiltration predicts better adjuvant chemotherapy response in MSI patients.
Zhen Ling   +9 more
wiley   +1 more source

EMQN best practice guidelines for analysis and reporting of microsatellite instability in solid tumours. [PDF]

open access: yesEur J Hum Genet
Gallon R   +11 more
europepmc   +1 more source

Finding More in Less: Precision Medicine for Pancreatic Cancer Using Residual Cytology Samples

open access: yesCytopathology, Volume 37, Issue 3, Page 275-283, May 2026.
The study evaluates the use of residual liquid‐based cytology (LBC) samples from pancreatic ductal adenocarcinoma (PDAC) for molecular analysis. It shows that LBC samples preserve nucleic acid quality and remain suitable for next‐generation sequencing (NGS) and MSI testing even after prolonged storage, underscoring their value when other samples are ...
Raquel Antón‐Peñalver   +17 more
wiley   +1 more source

Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug‐Target Mendelian Randomization Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4091-4099, May 2026.
ABSTRACT Aims Observational studies show metformin use associated with lower cancer risk, although experimental evidence is inconsistent. To provide genetic validation for repositioning of metformin in cancer prevention, we assessed genetically proxied effects of putative metformin targets on cancer outcomes using a drug‐target Mendelian randomization (
Xingyu Shen   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy